Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: Results of the etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) trial

Journal of Rheumatology

Volumn 34, Issue 2, 2007, Pages 408-420

  Baraf, Herbert S B ^a   Fuentealba, Carlos ^b   Greenwald, Maria ^c   Brzezicki, Jan ^d   O'Brien, Katherine ^e   Soffer, Beth ^e   Polis, Adam ^e   Bird, Steven ^e   Kaur, Amarjot ^e   Curtis, Sean P ^e  

^a Center for Rheumatology and Bone Research   (United States)

^b HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^c Desert Medical Advances   (United States)

^d Oddziall Reumatologii Wojewodzki Szpital Zespolony ^*  (Poland)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Diclofenac; Etoricoxib; Gastrointestinal; Osteoarthritis; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; ETORICOXIB; IBUPROFEN; NAPROXEN; PARACETAMOL; PROTECTIVE AGENT; ROFECOXIB; VALDECOXIB;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERY THROMBOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; LIVER FUNCTION TEST; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEOARTHRITIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH PERFORATION; STOMACH ULCER; SUDDEN DEATH; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; UPPER ABDOMINAL PAIN; UPPER GASTROINTESTINAL BLEEDING; VEIN THROMBOSIS; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PYRIDINES; SULFONES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 33846956072     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part I: the disease and its risk factors. Ann Intern Med 2000;133:635-46.
2. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15.
3. Hinton R, Moody RL, Davis AW, Thomas SF. Osteoarthritis: diagnosis and therapeutic considerations. Am Fam Physician 2002;65:841-8.
4. Langman M, Kahler KH, Kong SX, et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioner's database in the United Kingdom. Pharmacoepidemiol Drug Saf 2001;410:517-24.
5. Singh G, Ramey DR. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. J Rheumatol 1998;25 Suppl 51:8-16.
6. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124:288-92.
7. Lanas A. Cyclo-oxygenase-1/cyclo-oxygenase-2 nonselective non-steroidal anti-inflammatory drugs: epidemiology of gastrointestinal events. Digest Liver Dis 2001;33 Suppl 2:S28-S34.
8. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
9. Buchanan WW, Brooks AL. Predictions of organ system toxicity with antirheumatic drug therapy. In: Bellamy N, editor. Prognosis in the rheumatic diseases. Dordrecht: Kluwer Academic Publishers; 1991:403-50.
10. Straus WL, Ofman JJ. Gastrointestinal toxicity associated with nonsteroidal anti-inflammatory drugs. Epidemiologic and economic issues. Gastroenterol Clin North Am 2001;30:895-920.
11. Hawkey CJ. Quality of life in users of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol Suppl 1996;221:23-4.
12. Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005;3:489-98.
13. Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98:1725-33.
14. Hunt RH, Harper S, Callegari P, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201-10.
15. Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004;20:1899-908.
16. Matsumoto AK, Cavanaugh PF Jr. Etoricoxib. Drugs Today Barc 2004;40:395-414.
17. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
18. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2037-46.
19. Cannon CP, Curtis SP, Bolognese JA, Laine L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib vs. diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 2006;152:237-45.
20. Collaborative overview of randomised trials of antiplatelet therapy - 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106. Erratum in: BMJ 1994;308:1540.
21. Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reiein AS. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005;21:715-22.
22. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
23. Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. Curr Med Res Opin 2004;20:1539-48.
24. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998;17:873-90.
25. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927;22:209-12.
26. Curtis SP, Bockow B, Fisher C, et al. Etoricoxib in the treatment of osteoarthritis over 52 weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet Disord 2005;6:58.
27. Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989;149:1019-22.
28. de Pouvourville G, Tasch RF. The economic consequences of NSAID-induced gastrointestinal damage. Eur J Rheumatol Inflamm 1993;13:33-40.
29. Knill-Jones RP. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville. Scand J Rheumatol Suppl 1992;96:59-62.
30. Johnson RE, Hornbrook MC, Hooker RS, Woodson GT, Shneidman R. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation. Pharmaeoeconomics 1997;12:76-88.
31. Moore RA. Phillips CJ. Cost of NSAID adverse effects to the UK National Health Service. J Med Economics 1999;2:45-55.
32. Zhao SZ, Arguelles LM, Dedhiya SD, Morgan DG. Healthcare utilization associated with dyspepsia in patients with arthritis. Am J Manag Care 1999;5:1285-95.
33. Rahme E, Toubouli Y, Hunsche E. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada. Rheumatology Oxford 2006;45:903-10.
34. Zhao SZ, Wentworth C, Burke TA, Makuch RW. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf 2004;13:277-87.
35. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995;22:820-7.
36. Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyneratic drug toxicity. Toxicol Appl Pharmacol 2003;192:307-22.
37. Cataflam® diclofenac potassium immediate-release tablets: Voltaren® diclofenac sodium delayed-release (enteric-coated) tablets; Voltaren*-XR diclofenac sodium extended-release tablets [package insert]. In: Physicians desk reference. 54th cd. Montvale. NJ: Medical Economics Company, Inc.; 2000:2004-8.
38. Tang W. The metabolism of diclofenac - enzymology and toxicology perspectives. Curr Drug Metab 2003;4:319-29.
39. Jenkins JK, Seligman PJ. Analysis and recommendations for agency action regarding nonsteroidal anti-inflammatory drugs and cardiovascular risk. [Internet. Accessed October 16, 2006] Available from: http://www.rda.gov/cdcr/ drug/infopage/CUX2/NSAIDdecisionMemo. pdf. 1-19. 4-6-2005.
40. Food and Drug Administration. COX-2 selective (includes Bextra, Celebrex. and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). [Internet. Accessed October 16, 2006.] Available from: http://www.fda.gov/cdcr/ drug/infopage/COX2/default.htm.n-15-2005.
41. EMEA. European Medicines Agency concludes action on COX-2 inhibitors. London. Doc Ref EMEA/2077M2005 2005 Jun 27: [Internet. Accessed October 16. 2006.] Available from: http://www.emea.eu.int/pdfs/human/press/pr/20776605en.pdf
42. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-81.
43. Breedveld FC. Osteoarthritis - the impact of a serious disease. Rheumatology Oxford 2004;43 Suppl 1:i4-i8.
44. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey [comment]. Am J Manag Care 2002;8 Suppl:S383-S391.